** Shares of drugmaker AbCellera ABCL.O rise 6.2% to $4.64 in premarket trading

** Co says it has started dosing patients in a mid-stage trial for ABCL635, its experimental drug aimed at treating hot flashes and other moderate-to-severe symptoms linked to menopause

** Drug aims to ease hot flashes and other moderate-to-severe menopause symptoms, per co

** Co's ABCL635 offers non-hormonal alternative for women avoiding hormone therapy

** Trial will enroll 80 postmenopausal women; results expected in Q3 2026 - ABCL

** As of last close, stock up ~17% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))